Loria P, Bozzoli M, Concari M, Guicciardi M E, Carubbi F, Bertolotti M, Piani D, Nistri A, Angelico M, Romani M, Carulli N
Dipartimento di Medicina Interna, Universita di Modena, Italy.
Hepatology. 1997 Jun;25(6):1306-14. doi: 10.1002/hep.510250601.
This study aimed to determine the effect in humans of taurohyodeoxycholic acid, a 6alpha-hydroxylated bile acid with hydrophilic properties, on bile lipid secretion. Four cholecystectomized patients who had gallstones and an interrupted enterohepatic circulation were intraduodenally infused with taurohyodeoxycholic and tauroursodeoxycholic acids on separate occasions at a dose of 0.8 to 1 g/h for 3 hours. In hourly bile samples collected for 8 hours after the beginning of the infusion, biliary bile acid composition (by high-performance liquid chromatography), biliary lipid concentrations (by standard methods), and distribution of biliary carriers (by gel chromatography) were evaluated. Blood liver function tests were performed before and after the infusions. Taurohyodeoxycholic and tauroursodeoxycholic acids became the predominant biliary bile acids in all patients except for one infused with taurohyodeoxycholic acid. Taurohyodeoxycholic acid stimulated significantly greater (P < .05) cholesterol and phospholipid secretion per unit of secreted bile acid (0.098 and 0.451 micromol/micromol, respectively) compared with tauroursodeoxycholic acid (0.061 micromol/micromol for cholesterol and 0.275 micromol/micromol for phospholipids). The secretory ratio between phospholipid and cholesterol was significantly higher after infusion of taurohyodeoxycholic acid (3.88 micromol/micromol) compared with taroursodeoxycholic acid (3.09 micromol/micromol) (P < .05). Biliary enrichment with taurohyodeoxycholic acid was positively related with percent concentration of phospholipids but not with that of cholesterol. The opposite trend was observed in tauroursodeoxycholic acid-enriched biles. In both taurohyodeoxycholic acid- and tauroursodeoxycholic acid-rich bile, 80% to 90% of cholesterol was carried in a gel-chromatographic fraction corresponding to an apparent molecular weight of 80 to 200 kd. No alteration in liver function test results was observed after taurohyodeoxycholic acid infusion. In conclusion, taurohyodeoxycholic acid stimulates greater cholesterol and phospholipid secretion than tauroursodeoxycholic acid, but with a higher phospholipid/cholesterol secretory ratio. In bile enriched with both bile acids, biliary cholesterol is transported in non-micellar aggregates. Finally, in the conditions of our study, taurohyodeoxycholic acid was not hepatotoxic.
本研究旨在确定牛磺猪去氧胆酸(一种具有亲水性的6α-羟基化胆汁酸)对人体胆汁脂质分泌的影响。4例胆囊切除且患有胆结石并伴有肠肝循环中断的患者,分别在不同时间十二指肠内输注牛磺猪去氧胆酸和牛磺熊去氧胆酸,剂量为0.8至1 g/h,持续3小时。在输注开始后8小时内每小时采集胆汁样本,评估胆汁酸成分(通过高效液相色谱法)、胆汁脂质浓度(通过标准方法)以及胆汁载体的分布(通过凝胶色谱法)。在输注前后进行血液肝功能测试。除1例输注牛磺猪去氧胆酸的患者外,牛磺猪去氧胆酸和牛磺熊去氧胆酸在所有患者中均成为主要的胆汁胆汁酸。与牛磺熊去氧胆酸(胆固醇为0.061 μmol/μmol,磷脂为0.275 μmol/μmol)相比,牛磺猪去氧胆酸每分泌单位胆汁酸所刺激分泌的胆固醇和磷脂显著更多(分别为0.098和0.451 μmol/μmol)(P < 0.05)。输注牛磺猪去氧胆酸后磷脂与胆固醇的分泌比值(3.88 μmol/μmol)显著高于输注牛磺熊去氧胆酸后(3.09 μmol/μmol)(P < 0.05)。胆汁中牛磺猪去氧胆酸的富集与磷脂的百分比浓度呈正相关,但与胆固醇的百分比浓度无关。在牛磺熊去氧胆酸富集的胆汁中观察到相反的趋势。在富含牛磺猪去氧胆酸和牛磺熊去氧胆酸的胆汁中,80%至90%的胆固醇以凝胶色谱分离组分的形式携带,其表观分子量对应于80至200 kd。输注牛磺猪去氧胆酸后未观察到肝功能测试结果的改变。总之,与牛磺熊去氧胆酸相比,牛磺猪去氧胆酸刺激分泌更多的胆固醇和磷脂,但磷脂/胆固醇分泌比值更高。在富含这两种胆汁酸的胆汁中,胆汁胆固醇以非微团聚集体的形式运输。最后,在我们的研究条件下,牛磺猪去氧胆酸没有肝毒性。